Immix Biopharma raises $130M in stock offering for CAR-T amyloidosis therapy
What's the deal? Immix BiopharmaDealroom has a profile for this one. Try Dealroom → priced a $125 million underwritten public stock offering, selling 11,363,637 shares at $11.00 each. The Los Angeles biotech, listed on Nasdaq as IMMX, expects the offering to close on or about September 30, 2026.
Who's in? New and existing institutional backers joined, including Eventide Asset ManagementDealroom has a profile for this one. Try Dealroom →, Janus Henderson Investors, Ridgeback Capital Investments, and Wellington Management. J.P. MorganDealroom has a profile for this one. Try Dealroom → acted as sole book-running manager.
What's the endgame? Immix will use the proceeds to fund development of NXC-201, its lead candidate, plus working capital and general corporate purposes. NXC-201 is a BCMA-targeted CAR-T cell therapy for relapsed/refractory AL Amyloidosis, a disease in which the immune system produces toxic light chains that clog the heart, kidney, and liver.
Why now? NXC-201 is being tested in NEXICART-2, a US multi-centre study with a potentially registrational design. The therapy holds Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations from the US Food and Drug Administration, plus Orphan Drug Designation from the FDA and Europe's EMA.
The signal: This is a large raise by biotech standards, sitting in roughly the top half of comparable rounds. The scale, and the calibre of the institutional names, suggests investor conviction in CAR-T approaches to rare, hard-to-treat diseases as Immix pushes toward a registrational trial.
Read more: marketscreener.com
Image credit: Generated with Gemini
